290 patents
Page 5 of 15
Utility
Two-dimensional LC-MS/MS Systems
11 Aug 22
The present invention relates to a novel analytical method for detecting one or more analytes in a source sample by continuous flow 2D LC-MS/MS using a single LC system.
Wei-Lien Chuang, Felipe Gazos Lopes, Joshua Pacheco, Gerard Sanderink
Filed: 29 May 20
Utility
Tropomyosin-related kinase (TRK) inhibitors
9 Aug 22
Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease.
John L. Kane, Jr., Gloria Matthews, Markus Metz, Michael Kothe, Jinyu Liu, Andrew Scholte
Filed: 25 Sep 20
Utility
Oligosaccharide-protein Conjugates
4 Aug 22
Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI.
Luis Z. AVILA, Clark Q. PAN, Patrick FINN, John HARRAHY, Qun ZHOU, Yunxiang ZHU, Paul A. KONOWICZ, Duncan E. PATERSON, Andreas PEER, Joseph P. KUTZKO, Michael R. REARDON, James E. STEFANO, Xiaoyang ZHENG, Robert J. MILLER, Lauren YOUNG
Filed: 14 Feb 22
Utility
Methods for Enhanced Removal of Impurities During Protein a Chromatography
4 Aug 22
Provided herein are methods relating to the purification of a polypeptide comprising an Fc region (e.g., an antibody) via protein A chromatography; methods relating to the use of a wash solution comprising a benzoate salt and/or benzyl alcohol during protein A chromatography; and methods of adjusting a harvest using sodium benzoate prior to protein A chromatography.
Carl A. BEIGIE
Filed: 17 Dec 21
Utility
Methods for improving cell viability in a production bioreactor
19 Jul 22
Provided herein are methods of predicting the effect of a concentration of a sensitizer on cell viability in a production bioreactor, methods of improving cell viability in a production bioreactor, methods of predicting cell viability in a production bioreactor, and methods for culturing a cell in a production bioreactor.
Jonathan Wang, Neha Shah, Jason Walther, Jiuyi Lu, Timothy Johnson, Yukun Ren, Jean McLarty
Filed: 15 Mar 19
Utility
Deuterated Colony Stimulating FACTOR-1 Receptor (CSF-1R) Inhibitors
30 Jun 22
John L. Kane, JR., Nellwyn A. Hagan, Maria A. Fitzgerald
Filed: 11 Feb 22
Utility
Oligosaccharides Comprising an Aminooxy Group and Conjugates Thereof
30 Jun 22
The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group.
Yunxiang ZHU, Seng H. CHENG, Canwen JIANG, Luis Z. AVILA
Filed: 10 Sep 21
Utility
Methods for Treating Osteogenesis Imperfecta
23 Jun 22
The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGFβ).
Brendan Lee, Kuber T. Sampath
Filed: 9 Dec 21
Utility
Assays for Detecting the Presence or Amount of an Anti-drug Antibody
16 Jun 22
Methods and kits for detecting antibodies (e.g., anti-drug antibodies).
Ryan Grabert, Susan Richards, Valerie Theobald, Yuanxin Xu, Jad Zoghbi
Filed: 23 Nov 21
Utility
Methods of Culturing a Mammalian Cell
12 May 22
Provided herein are methods of culturing a mammalian cell in a liquid medium including poloxamer-188 at a concentration of 1.8 g/L or at a greater concentration than 1.8 g/L more or a liquid medium that includes a poloxamer-188 concentration that is selected based on one or more factors selected from the group of: pore size, pore type, gas flow rate, viable cell density in the medium, and markers related to cell stress.
Christopher Hwang, Timothy Johnson, Jason Walther, Cheng Cheng, Jonathan Wang, Neha Shah, Seul-A Bae
Filed: 11 Jan 22
Utility
Modified-IgG antibodies that bind transforming growth factor-β1 with high affinity, avidity and specificity
10 May 22
A modified IgG antibody binds and neutralizes TGFβ1 selectively and with high affinity and avidity.
Huawei Qiu, Julie Bird
Filed: 3 Mar 16
Utility
scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificity
10 May 22
An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity.
Huawei Qiu, Clark Pan, Julie Bird
Filed: 30 Oct 19
Utility
Site-specific Glycoengineering of Targeting Moieties
21 Apr 22
The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide.
Luis AVILA, Clark PAN, Huawei QIU, Qun ZHOU
Filed: 29 Mar 21
Utility
Methods of culturing a mammalian cell
19 Apr 22
Provided herein are methods of culturing a mammalian cell in a liquid medium including poloxamer-188 at a concentration of 1.8 g/L or at a greater concentration than 1.8 g/L more or a liquid medium that includes a poloxamer-188 concentration that is selected based on one or more factors selected from the group of: pore size, pore type, gas flow rate, viable cell density in the medium, and markers related to cell stress.
Christopher Hwang, Timothy Johnson, Jason Walther, Cheng Cheng, Jonathan Wang, Neha Shah, Seul-A Bae
Filed: 21 Dec 15
Utility
Pharmaceutical Formulations of Tropomyosin Related Kinase (TRK) Inhibitors
14 Apr 22
Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed.
Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos, Chris Ho
Filed: 20 Aug 21
Utility
Treatment of Ciliopathies Using Inhibitors of Glucosylceramide Synthase (GCS)
14 Apr 22
This disclosure relates to a method of treating a ciliopathy in a subject, the method comprising administering to the subject an effective amount of a quinuclidine compound.
Oxana IBRAGHIMOV-BESKROVNAYA, Nikolay O. BUKANOV, Hervé HUSSON, Sarah E. MORENO
Filed: 4 Feb 20
Utility
Human Pah Expression Cassette for Treatment of Pku by Liver-directed Gene Replacement Therapy
14 Apr 22
Provided herein are expression cassettes for expressing a transgene in a liver cell, wherein the transgene encodes a PAH polypeptide.
Sirkka R.M. KYOSTIO-MOORE
Filed: 30 Sep 21
Utility
Methods for Enhancing Immunosuppressive Therapy by Multiple Administration of Alpha Beta Tcr-binding Polypeptide
31 Mar 22
The present disclosure is related to improved methods for use of a humanized binding polypeptide specific for the alpha beta T cell receptor (αβ-TCR).
Gregor Blank, Rubert Handgretinger, Karin Schilbach, Gina Lacorcia, Daniel Snell, Andreas Menrad
Filed: 8 Sep 21
Utility
Multivariate Spectral Analysis and Monitoring for Biomanufacturing
31 Mar 22
The disclosure features methods that include obtaining a vibrational spectrum of a solution in a biological manufacturing system, analyzing the vibrational spectrum using a first chemometrics model to determine a value of a first quality attribute associated with the solution, analyzing the vibrational spectrum using a second chemometrics model to determine a value of a second quality attribute associated with the solution, and adjusting at least one parameter of a purification unit of the biological manufacturing system based on at least one of the values of the first and second quality attributes.
Dhanuka Pulasthi Wasalathanthri, Jagdish C. Tewari, Xuezhen Kang, Marina Hincapie, Shawn L. Barrett, Julie Susanne Pollock
Filed: 7 Dec 21
Utility
Glycoengineered Antibody Drug Conjugates
24 Mar 22
The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide.
Luis Z. Avila, Qun Zhou
Filed: 16 Aug 21